Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN2109 in advanced solid tumors
NCT06332430Phase 1Recruiting
- Sponsor
- Canwell Biotech Ltd.
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CAN2109 in solid tumor and lymphoma, sponsored by Canwell Biotech Ltd. Primary endpoints: Safety at 12 months, Recommended Phase 2 Dose at 12 months and 1 more. Started May 2024; status: recruiting.
02
Drugs
CAN2109
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT06332430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06332430.